Laura Pina-Camacho1, Covadonga M Díaz-Caneja2, Pilar A Saiz3, Julio Bobes3, Iluminada Corripio4, Eva Grasa4, Roberto Rodriguez-Jimenez5, Miryam Fernández6, Julio Sanjuán7, Aurelio García-López8, Cecilia Tapia-Casellas2, María Álvarez-Blázquez2, David Fraguas2, Marina Mitjans9, Bárbara Arias9, Celso Arango2. 1. CIBER del área de Salud Mental (CIBERSAM), España; Servicio de Psiquiatría del Niño y del Adolescente, Departamento de Psiquiatría, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, IiSGM, Madrid, España; Department of Child and Adolescent Psychiatry, Institute of Psychiatry, King's College London, Londres, Reino Unido. Electronic address: lpina.iisgm@gmail.com. 2. CIBER del área de Salud Mental (CIBERSAM), España; Servicio de Psiquiatría del Niño y del Adolescente, Departamento de Psiquiatría, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, IiSGM, Madrid, España. 3. CIBER del área de Salud Mental (CIBERSAM), España; Área de Psiquiatría, Universidad de Oviedo, Oviedo, España; Instituto Universitario de Neurociencias del Principado de Asturias (INEUROPA), Oviedo, España. 4. CIBER del área de Salud Mental (CIBERSAM), España; Servicio de Psiquiatría, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma, Barcelona, España. 5. CIBER del área de Salud Mental (CIBERSAM), España; Servicio de Psiquiatría, Instituto de Investigación Hospital 12 de octubre (i+12), Universidad Complutense, Madrid, España. 6. CIBER del área de Salud Mental (CIBERSAM), España; Servicio de Psiquiatría, Hospital Universitario de Santiago Apóstol, Universidad del País Vasco, Vitoria, España. 7. CIBER del área de Salud Mental (CIBERSAM), España; Departamento de Psiquiatría, Hospital Clínico INCLIVA, Universidad de Valencia, Valencia, España. 8. CIBER del área de Salud Mental (CIBERSAM), España; Servicio de Psiquiatría, Hospital Universitario Ramón y Cajal, Madrid, España. 9. CIBER del área de Salud Mental (CIBERSAM), España; Unitat d́Antropologia, Departament de Biologia Animal, Facultat de Biologia e Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, España.
Abstract
AIM: Weight gain is an important and common side effect of second generation antipsychotics (SGAs). Furthermore, these drugs can induce other side effects associated with higher cardiovascular morbidity and mortality, such as insulin resistance, diabetes or metabolic syndrome. Preliminary studies show that inter-individual genetic differences produce varying degrees of vulnerability to the different SGA-induced side effects. The Second-generation antipsychotic Long-term treatment Metabolic side effects (SLiM) study aims to identify clinical, environmental and genetic factors that explain inter-individual differences in weight gain and metabolic changes in drug-naïve patients after six months of treatment with SGAs. MATERIALS AND METHODS: The SLIM study is a multicenter, observational, six-month pharmacogenetic study where a cohort of 307 drug-naïve paediatric and adult patients (age range 8.8-90.1 years) and a cohort of 150 age- and sex- matched healthy controls (7.8-73.2 years) were recruited. RESULTS: This paper describes the rationale, objectives and design of the study and provides a description of the sample at baseline. CONCLUSIONS: Results from the SLiM study will provide a better understanding of the clinical, environmental, and genetic factors involved in weight gain and metabolic disturbances associated with SGA treatment.
AIM: Weight gain is an important and common side effect of second generation antipsychotics (SGAs). Furthermore, these drugs can induce other side effects associated with higher cardiovascular morbidity and mortality, such as insulin resistance, diabetes or metabolic syndrome. Preliminary studies show that inter-individual genetic differences produce varying degrees of vulnerability to the different SGA-induced side effects. The Second-generation antipsychotic Long-term treatment Metabolic side effects (SLiM) study aims to identify clinical, environmental and genetic factors that explain inter-individual differences in weight gain and metabolic changes in drug-naïve patients after six months of treatment with SGAs. MATERIALS AND METHODS: The SLIM study is a multicenter, observational, six-month pharmacogenetic study where a cohort of 307 drug-naïve paediatric and adult patients (age range 8.8-90.1 years) and a cohort of 150 age- and sex- matched healthy controls (7.8-73.2 years) were recruited. RESULTS: This paper describes the rationale, objectives and design of the study and provides a description of the sample at baseline. CONCLUSIONS: Results from the SLiM study will provide a better understanding of the clinical, environmental, and genetic factors involved in weight gain and metabolic disturbances associated with SGA treatment.
Keywords:
Agentes antipsicóticos; Antipsychotic Agents; Aumento de peso; Drug-Related Side Effects and Adverse Reactions; Efectos secundarios y reacciones adversas a medicamentos; Farmacogenética; Metabolic Syndrome; Pharmacogenetics; Síndrome metabólico; Weight Gain
Authors: Carolin Hoffmann; Jo Stevens; Shenghua Zong; Daan van Kruining; Abhishek Saxena; Cem İsmail Küçükali; Erdem Tüzün; Nazlı Yalçınkaya; Marc De Hert; Emiliano González-Vioque; Celso Arango; Jon Lindstrom; Marc H De Baets; Bart P F Rutten; Jim van Os; Peter Molenaar; Mario Losen; Pilar Martinez-Martinez Journal: PLoS One Date: 2018-12-06 Impact factor: 3.240
Authors: Alfonso Sevillano-Jiménez; Guillermo Molina-Recio; Juan Antonio García-Mellado; María García-Rodríguez; Rafael Molina-Luque; Manuel Romero-Saldaña Journal: Front Nutr Date: 2022-08-10